KYTX (Kyverna Therapeutics) Total Equity : $266.59 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Total Equity?

Kyverna Therapeutics's total equity for the quarter that ended in Dec. 2024 was $266.59 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Kyverna Therapeutics Total Equity Historical Data

The historical data trend for Kyverna Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Total Equity Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Equity

-46.25

-74.00

-131.40

266.59

Kyverna Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Equity	Get a 7-Day Free Trial					-131.40	360.99	333.51	302.71	266.59

Kyverna Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Kyverna Therapeutics's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	304.645	-	38.058
	=	266.59

Kyverna Therapeutics's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	304.645	-	38.058
	=	266.59

Kyverna Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.